DOD Biotech Public Company Limited (SET: DOD) has announced its 2021 consolidated financial statement through the Stock Exchange of Thailand as follows;
| Yearly | 2021 | 2020 |
| Net Profit (Loss) Million Baht |
49.79 | 141.25 |
| Earning Per Share (Baht) | 0.12 | 0.34 |
| % Change | -64.75 | |
DOD reported a net profit of 49.79 million baht in 2021, decreased 64.75% from a net profit of 141 million baht in 2020. The decrease was mainly due to the decreasing revenue from sale and increased other expenses.
DOD saw a slight decrease in 2021 revenue by 5.76% from 1,0177 million baht in 2020 to 1,015 million baht. Meanwhile, both selling expenses and administrative expenses all rose by 26.30% and 17.67%, respectively.
Other expenses rose 53.74% from 25.55 million baht in 2020 to 39.28 million baht in 2021. The company has record allowance for loss impairment and advance payment of fixed assets due to the company’s business restructuring.
In addition, the Board of Directors have resolved to omit a dividend payment for 2021.
